Intravitreal recombinant tissue plasminogen activator (r-TPA) 淵鑰簾鹹齋襯鬱廠衊觸(願淵糧築餘襯廠齋窪夢) = Intravitreal anti-VEGF therapy was performed, which led to the improvement of BCVA, 0.4 LogMAR OD, and the reduction of CNV size, as the OCTA report shows 築製衊獵鹽網網鹹鏇窪 (...
Synopsis Alteplase (recombinant tissue-type plasminogen activator) stimulates the fibrinolysis of blood clots by converting plasminogen to plasmin. The efficacy of intravenous alteplase in the early treatment of patients with acute myocardial infarction has been unequivocally proven, and recent results from ...
Alteplase (recombinant tissue plasminogen activator; rt-PA) is a thrombolytic agent that when given in an accelerated regimen with intravenous heparin has survival advantages compared with streptokinase in the treatment of acute myocardial infarction, as shown by the results of the Global Utilisation o...
阿替普酶; alteplase; Activase; 爱通立; rt-PA; tissue plasminogen activator; recombinant tissue plasminogen activator; Actilyse 药品类别 创新药; 生物; first-in-class 靶点 tissue plasminogen activator (tPA) 作用机制 重组tPA 药品简介 -- 研发机构 Boehringer Ingelheim ;Roche 最高研发阶段 全球...
Tissue plasminogen activator (t-PA/Alteplase) may be a useful pharmacological agent to improve the efficacy of manual irrigation of large, dense clots. The goal of the current study was to compare t-PA to sterile water for clot irrigation in an in vitro model. MATERIALS AND METHODS: In ...
Cathflo Activase (Alteplase, Genentech, San Francisco, California) is a recombinant tissue plasminogen activator (tPA) which is Food and Drug Administration approved for the restoration of function to central venous access devices when they have become clotted and blood is unable to be withdrawn. ...
名称来源p-INNList-59,1988;r-INNList-29,1989; 化学表述plasminogen activator (human tissue-type protein moiety), glycoform α CA登记号105857-23-6 分子式C2569H3894N746O781S40 结构式 品种类别血液系统>抗凝血及溶栓药>组织类纤溶酶原活化剂;...
Alteplase (recombinant tissue-type plasminogen activator) stimulates the fibrinolysis of blood clots by converting plasminogen to plasmin.The efficacy of intravenous alteplase in the early treatment of patients with acute myocardial infarction has been unequivocally proven, and recent results from the GUSTO...
Recombinant tissuetype plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset.The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Clark WM,Wissman,S,Albers GW,et al. Journal of the American ...
Metalyse as an injection has been compared with alteplase (an exact copy of the human tissue plasminogen activator made using recombinant technology) as an infusion (drip into a vein EMEA0.3 We can break the clot with alteplase, but that could also worsen the bleeding somewhere else. OpenSu...